CITATION REPORT List of articles citing



DOI: 10.7326/0003-4819-132-12-200006200-00002 Annals of Internal Medicine, 2000, 132, 933-7.

Source: https://exaly.com/paper-pdf/31662625/citation-report.pdf

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
57	Sildenafil cost effective versus no treatment. <i>Inpharma Weekly</i> , 2000 , &NA, 5		
56	Trends in the Rate of Self-Report and Diagnosis of Erectile Dysfunction in the United States 1990 1 998. <i>Disease Management and Health Outcomes</i> , 2001 , 9, 33-41		7
55	Sildenafil citrate: a therapeutic update. <i>Clinical Therapeutics</i> , 2001 , 23, 2-23	3.5	65
54	IMPROVEMENT IN EMOTIONAL WELL-BEING AND RELATIONSHIPS OF USERS OF SILDENAFIL. Journal of Urology, 2001 , 166, 1774-1778	2.5	69
53	Influenza. Cost of illness and considerations in the economic evaluation of new and emerging therapies. <i>Pharmacoeconomics</i> , 2001 , 19, 223-30	4.4	16
52	Review of patients with erectile dysfunction attending the Maudsley psychosexual clinic in 1999: The impact of sildenafil. <i>Sexual and Relationship Therapy</i> , 2002 , 17, 171-185	1.1	3
51	Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. <i>Diabetes Care</i> , 2002 , 25, 284-91	14.6	229
50	Management of Erectile Dysfunction. <i>Disease Management and Health Outcomes</i> , 2002 , 10, 431-452		5
49	Rationalising rationing: economic and other considerations in the debate about funding of Viagra. <i>Health Policy</i> , 2002 , 59, 53-63	3.2	35
48	Clinical update on sildenafil citrate. British Journal of Clinical Pharmacology, 2002, 53, 219-23	3.8	10
47	When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimerß dementia? A decision analysis. <i>Value in Health</i> , 2003 , 6, 542-50	3.3	16
46	Epidemiology of erectile dysfunction. International Journal of Impotence Research, 2003, 15, 63-71	2.3	240
45	Cost implications of sexual dysfunction: the female picture. <i>International Journal of Impotence Research</i> , 2004 , 16, 130-4	2.3	9
44	Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 1019-26	15.1	146
43	One of these things is not like the others: the idea of precedence in health technology assessment and coverage decisions. <i>Milbank Quarterly</i> , 2005 , 83, 193-223	3.9	24
42	Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2005 , 2, 848-55	1.1	30
41	The costs of caring for erectile dysfunction in a managed care setting: evidence from a large national claims database. <i>Journal of Urology</i> , 2005 , 174, 1948-52	2.5	20

(2015-2005)

40	Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. American Journal of Medicine, 2005 , 118, 850-7	2.4	58
39	Quality-of-Life Utility Values for Erectile Function and Sildenafil Treatment. <i>Clinical Drug Investigation</i> , 2005 , 25, 99-105	3.2	19
38	QALYs: are they helpful to decision makers?. <i>Pharmacoeconomics</i> , 2006 , 24, 947-52	4.4	41
37	Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. <i>American Journal of Clinical Dermatology</i> , 2006 , 7, 133-9	7.1	22
36	Cost-effectiveness of pediatric heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2006 , 25, 409-15	5.8	45
35	What decision-makers want and what they have been getting. Value in Health, 2006, 9, 181-5	3.3	27
34	Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <i>Journal of General Internal Medicine</i> , 2008 , 23, 509-16	4	26
33	Erectile dysfunction drug receipt, risky sexual behavior and sexually transmitted diseases in HIV-infected and HIV-uninfected men. <i>Journal of General Internal Medicine</i> , 2010 , 25, 115-21	4	17
32	Internal pudendal artery stenoses and erectile dysfunction: correlation with angiographic coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2010 , 76, 882-7	2.7	47
31	Incremental cost-effectiveness of various monthly doses of vardenafil. Value in Health, 2011 , 14, 97-101	1 3.3	5
30	Sexual function and dysfunction in older HIV-positive individuals. Sexual Health, 2011, 8, 502-7	2	3
30	Sexual function and dysfunction in older HIV-positive individuals. <i>Sexual Health</i> , 2011 , 8, 502-7 Insurance coverage for erectile dysfunction drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 19-		3
•			3 1 67
29	Insurance coverage for erectile dysfunction drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 19- Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors. <i>Journal of the American College of</i>	-2611	1
29	Insurance coverage for erectile dysfunction drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 19- Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2618-27 Endovascular therapy for vasculogenic erectile dysfunction. <i>Current Treatment Options in</i>	- 2 511 15.1	1 67
29 28 27	Insurance coverage for erectile dysfunction drugs. Clinical Pharmacology and Therapeutics, 2011, 89, 19- Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors. Journal of the American College of Cardiology, 2012, 60, 2618-27 Endovascular therapy for vasculogenic erectile dysfunction. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 193-202 Endovascular embolisation therapy in men with erectile impotence due to veno-occlusive	-2611 15.1 2.1	1 67 16
29 28 27 26	Insurance coverage for erectile dysfunction drugs. Clinical Pharmacology and Therapeutics, 2011, 89, 19- Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors. Journal of the American College of Cardiology, 2012, 60, 2618-27 Endovascular therapy for vasculogenic erectile dysfunction. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 193-202 Endovascular embolisation therapy in men with erectile impotence due to veno-occlusive dysfunction. European Journal of Radiology, 2013, 82, 504-7 A systematic review assessing the economic impact of sildenafil citrate (Viagra) in the treatment of	-2611 15.1 2.1 4.7	1 67 16 21

22	Sexual Dysfunction in Men and Women. 2016 , 785-830		1
21	The pharmacist role in improving the treatment of erectile dysfunction and its underlying causes. <i>Research in Social and Administrative Pharmacy</i> , 2019 , 15, 591-599	2.9	3
20	A Review of Economic Evaluations of Erectile Dysfunction Therapies. <i>Sexual Medicine Reviews</i> , 2020 , 8, 497-503	5.6	7
19	A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction. <i>European Journal of Health Economics</i> , 2020 , 21, 73-84	3.6	7
18	Do current radical innovation measures actually measure radical drug innovation?. <i>Scientometrics</i> , 2021 , 126, 1049-1078	3	3
17	Ethical issues in treatment of babies born at 22 weeks of gestation. <i>Archives of Disease in Childhood</i> , 2021 , 106, 1155-1157	2.2	5
16	The Economics of Viagra Revisited: The Price Is Right. <i>Urology</i> , 2021 ,	1.6	1
15	Genitourinary Complications. 2007 , 453-472		2
14	Sexual Dysfunction in Men and Women. 2011 , 778-816		2
13	IMPROVEMENT IN EMOTIONAL WELL-BEING AND RELATIONSHIPS OF USERS OF SILDENAFIL. Journal of Urology, 2001 , 1774-1778	2.5	1
12	Utilization effects of Rx-OTC switches and implications for future switches. <i>Health</i> , 2013 , 05, 1667-168	0 0.4	4
11	Tough choices: the cost-effectiveness of sildenafil. <i>Annals of Internal Medicine</i> , 2000 , 132, 994-5	8	7
10	Hypogonadism, erectile dysfunction and infertility in men. 2002, 147-200		
9	Therapy of erectile dysfunction (ED) with sildenafil improves quality of life (QoL) and partnership (QoP). 2004 , 83-100		1
8	Outcomes Research. 2012 , 140-156.e8		
7	Endovascular Approaches to Penile Arterial Revascularization for Vasculogenic Erectile Dysfunction. 2016 , 221-240		1
6	Ethical implications of the shifting borderline of viability. Seminars in Perinatology, 2021, 151531	3.3	1
5	Decision Analysis in Endocrinology. 2006 , 207-223		

CITATION REPORT

4 Epidemiology of Erectile Dysfunction. **2006**, 47-59

3	Cost-utility analysis: use QALYs only with great caution. <i>Cmaj</i> , 2003 , 168, 433-4	3.5	16
2	Organic erectile dysfunction in Taiwan: A nationwide, retrospective, age-matched nonrandomized study. <i>Urological Science</i> , 2018 , 29, 106	0.3	
1	Ethics of care for the micropreemies. Just because we can, should we?. <i>Seminars in Fetal and Neonatal Medicine</i> , 2022 , 101343	3.7	O